RxDoctor Payments Data

Neil Gilbert, MD

Neurology · Lathrup Village, MINPI 1053371658

Payments from drug & device makers

$37,969in general payments, 2019–2025

Across 1,609 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$10K
  • Amneal Pharmaceuticals LLC$3K
  • UCB, Inc.$3K
  • AbbVie$2K
  • Argenx US, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$9,35525%
  • Speaking & faculty fees$2,2776%
  • Travel & lodging$1,1513%
  • Food & beverage$24,97866%
  • Education$2081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC50$10,288
Amneal Pharmaceuticals LLC52$3,156
UCB, Inc.211$2,849
AbbVie(2 entities)130$1,872
Argenx US, Inc.39$1,789
Teva Pharmaceuticals USA, Inc.103$1,750
Novartis151$1,526
Neurocrine Biosciences, Inc.92$1,471
Biogen64$1,079
EMD Serono, Inc.67$1,040
Pfizer58$810
Sanofi37$725
Bristol Myers Squibb46$627
Vanda Pharmaceuticals Inc.33$600
Eisai Inc.36$590
Neurelis, Inc.33$583
SK Life Science, Inc.33$573
Takeda Pharmaceuticals U.S.A., Inc.23$436
AstraZeneca(2 entities)16$384
Lundbeck LLC19$379
Amgen(2 entities)23$374
Jazz Pharmaceuticals Inc.21$374
Impel Pharmaceuticals Inc.37$356
Sunovion Pharmaceuticals Inc.22$353
Adamas Pharmaceuticals, Inc.15$243
Acorda Therapeutics, Inc14$240
Tanabe Pharma America, Inc.11$239
Grifols USA, LLC4$210
Johnson & Johnson(2 entities)12$196
Catalyst Pharmaceuticals, Inc.12$195
Avanir Pharmaceuticals, Inc.11$193
Sumitomo Pharma America, Inc.10$177
Kyowa Kirin, Inc.10$173
E.r. Squibb & Sons, L.L.C.8$148
Axsome Therapeutics, Inc.7$140
Biohaven Pharmaceutical Holding Company Ltd.7$136
Acadia Pharmaceuticals Inc6$128
Supernus Pharmaceuticals, Inc.5$119
Aucta Pharmaceuticals, Inc.11$117
Aquestive Therapeutics, Inc.6$110
MDD US Operations, LLC5$92
Alnylam Pharmaceuticals Inc.4$88
Corium, LLC5$84
Greenwich Biosciences, Inc.2$81
Cycle Pharmaceuticals Inc5$81
Otsuka America Pharmaceutical, Inc.4$79
Biohaven Pharmaceuticals, Inc.5$76
Livanova USA, Inc.2$62
Vertical Pharmaceuticals, LLC4$57
Upsher-smith Laboratories LLC3$52
Zogenix Inc.3$43
Aprecia Pharmaceuticals, LLC2$41
Avion Pharmaceuticals3$40
Genentech USA, Inc.2$36
Octapharma USA, Inc.1$34
GE HealthCare1$32
Bayer2$31
Otter Pharmaceuticals, LLC1$27
Sanofi-aventis U.S. LLC2$27
Merz North America, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,969 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$516,238
Medicare patients
672
Services billed
7,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab18$141,643
AustedoDeutetrabenazine23$129,136
VumerityDiroximel Fumarate15$127,443
Austedo XrDeutetrabenazine14$94,407
NuplazidPimavanserin Tartrate14$68,841
AptiomEslicarbazepine Acetate39$50,811
RytaryCarbidopa/Levodopa16$22,687
Emgality PenGalcanezumab-Gnlm11$8,918
Pregabalin640$8,228
Carbidopa-LevodopaCarbidopa/Levodopa254$7,175
Lacosamide104$6,991
Midodrine Hcl69$5,539
Levetiracetam198$4,799
Primidone151$4,526
Pyridostigmine Bromide29$4,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,750$223,54337 claims
BiogenVumerity$1,079$127,44315 claims
Acadia Pharmaceuticals IncNuplazid$128$68,84114 claims
Sunovion Pharmaceuticals Inc.Aptiom$353$50,81139 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$3,156$26,98545 claims
Upsher-smith Laboratories LLCTopiramate$52$3,818275 claims
Lilly USA, LLCOlanzapine$10,288$1,881100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Lathrup Village

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →